The supplements company Telomerase Activation Sciences Inc. has taken its share of reputational licks from Brian Egan, a former TAS executive who says the pill-maker’s marquee product gave him prostate cancer. TAS’ fortunes improved a bit last week, though, when one judge blocked a class action lawsuit spearheaded by Egan, and another ruled that TAS’ libel suit against Egan can move forward.
In an order dated Sept. 5 but issued on Sept. 17, New York Supreme Court Justice Eileen Bransten refused to certify a class action lawsuit alleging that TAS deceptively marketed TA-65, an antiaging supplement sold widely online. The judge ruled that Egan, the lead plaintiff, failed to show that numerous New York plaintiffs got duped by the same advertisement for TA-65, so the case isn’t amenable to class action treatment.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
